Suraksha Diagnostic Ltd
Incorporated in 2005, Suraksha Diagnostic offers an integrated pathology, radiology testing, and medical consultancy services solution.[1]
- Market Cap ₹ 1,371 Cr.
- Current Price ₹ 263
- High / Low ₹ 334 / 224
- Stock P/E 40.3
- Book Value ₹ 48.0
- Dividend Yield 0.00 %
- ROCE 17.5 %
- ROE 14.7 %
- Face Value ₹ 2.00
Pros
- Company has delivered good profit growth of 33.1% CAGR over last 5 years
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Part of BSE Healthcare
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| 132 | 151 | 158 | 140 | 223 | 190 | 219 | 249 | 301 | |
| 105 | 115 | 123 | 115 | 175 | 142 | 144 | 166 | 206 | |
| Operating Profit | 27 | 36 | 34 | 25 | 48 | 48 | 74 | 84 | 95 |
| OPM % | 20% | 24% | 22% | 18% | 22% | 25% | 34% | 34% | 32% |
| 1 | 1 | 2 | -1 | 2 | 1 | 1 | 4 | 4 | |
| Interest | 4 | 2 | 2 | 2 | 2 | 10 | 10 | 9 | 12 |
| Depreciation | 12 | 12 | 13 | 16 | 15 | 32 | 33 | 35 | 40 |
| Profit before tax | 12 | 23 | 21 | 6 | 33 | 8 | 33 | 44 | 47 |
| Tax % | 28% | 17% | 28% | -1% | 28% | 9% | 25% | 24% | 28% |
| 9 | 19 | 15 | 6 | 24 | 7 | 24 | 33 | 34 | |
| EPS in Rs | 130.00 | 276.09 | 220.43 | 93.77 | 344.20 | 104.20 | 353.33 | 6.42 | 6.54 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 8% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 17% |
| 3 Years: | 17% |
| TTM: | 21% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 33% |
| 3 Years: | 59% |
| TTM: | 1% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -18% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | 16% |
| Last Year: | 15% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 10 | 10 |
| Reserves | 79 | 96 | 111 | 118 | 141 | 148 | 172 | 204 | 239 |
| 27 | 22 | 13 | 18 | 21 | 99 | 92 | 89 | 128 | |
| 33 | 43 | 42 | 28 | 32 | 29 | 30 | 30 | 72 | |
| Total Liabilities | 145 | 168 | 173 | 171 | 201 | 282 | 302 | 333 | 450 |
| 96 | 127 | 128 | 119 | 119 | 195 | 211 | 215 | 285 | |
| CWIP | 6 | 0 | 0 | 0 | 1 | 2 | 1 | 6 | 35 |
| Investments | 10 | 2 | 5 | 6 | 0 | 0 | 1 | 3 | 6 |
| 33 | 38 | 39 | 46 | 80 | 84 | 88 | 109 | 123 | |
| Total Assets | 145 | 168 | 173 | 171 | 201 | 282 | 302 | 333 | 450 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| 31 | 24 | 42 | 45 | 61 | 63 | 80 | |||
| -20 | -28 | -44 | -22 | -35 | -39 | -51 | |||
| -10 | 3 | 1 | -24 | -26 | -24 | -28 | |||
| Net Cash Flow | 1 | -1 | -0 | -1 | 0 | -1 | 1 | ||
| Free Cash Flow | 15 | 5 | 24 | 32 | 22 | 28 | 30 | ||
| CFO/OP | 111% | 100% | 97% | 109% | 94% | 88% | 99% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 14 | 16 | 14 | 16 | 12 | 9 | 15 | 22 | 30 |
| Inventory Days | 90 | 107 | 93 | 62 | 38 | 81 | 89 | 101 | 82 |
| Days Payable | 256 | 176 | 227 | 177 | 84 | 184 | 192 | 176 | 196 |
| Cash Conversion Cycle | -151 | -54 | -120 | -99 | -34 | -95 | -88 | -53 | -84 |
| Working Capital Days | -9 | 6 | -35 | -19 | -15 | -48 | -36 | -14 | -23 |
| ROCE % | 21% | 18% | 8% | 23% | 9% | 17% | 18% | 17% |
Insights
In beta| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Number of Collection Centres Number |
|
||||
| Number of Diagnostic Centres Number |
|||||
| Number of Doctors (Radiologist & Pathologist) Number |
|||||
| Number of Imaging Machines (MRI + CT) Number |
|||||
| Number of Laboratories Number |
|||||
| Number of Patients Served Million patients |
|||||
| Number of Tests per Patient Tests per patient |
|||||
| Number of Tests Performed Million tests |
|||||
Extracted by Screener AI
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
1d - Certificate under Regulation 74(5) of SEBI (Depositaries and Participants) Regulations, 2018 for the quarter ended 30 June, 2026.
-
Closure of Trading Window
15 Jun - Trading window closed from 1 July 2026 until 48 hours after Q1 FY27 results.
-
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
9 Jun - Ms. Mamta Jain resigned as Company Secretary and Compliance Officer; last working day 15 July 2026.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
27 May - Transcript of the Earning Call held on Friday, 22 May 2026 with respect to the Audited (Standalone and Consolidated) Financial results of the Company for …
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
22 May - Submitted Annual Secretarial Compliance Report for FY ended 31 March 2026; no non-compliances reported.
Concalls
-
May 2026Transcript PPT
-
Feb 2026Transcript PPT
-
Nov 2025Transcript PPT REC
-
Aug 2025Transcript PPT
-
Jun 2025Transcript PPT
-
Feb 2025Transcript PPT
-
Dec 2024Transcript PPT
-
Dec 2024TranscriptAI SummaryPPT
Business Model:[1][2][3]
a) Integrated Services:
Offers a one-stop solution for pathology, radiology, and medical consultancy services.
b) Comprehensive Testing:
Provides 1,000+ pathology tests and 450+ radiology tests.
c) Hub and Spoke Model:
Operates through 1 Central Reference Lab, 7 Satellite Labs (co-located with hub centres), 16 Hub Centres, and 46 Spoke Centres (34 Small, 12 Medium, 6 PPP), with 193 Collection Centres and 4 Company Owned Collection Centres.
d) Omni-channel Consultation:
Combines online and offline medical consultation services, leveraging its polyclinics with 1,000+ doctors.
e) B2C-Focused Revenue Model:
Primarily serves individual patients,
with some revenue from B2B contracts.